Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy

This publication has 25 references indexed in Scilit:

• Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
  Journal of Clinical Oncology, 2008
• HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
  Annals of Oncology, 2007
• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
  Annals of Oncology, 2007
• Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer
  The Oncologist, 2005
• Trastuzumab in breast cancer.
  2004
• Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
  JNCI Journal of the National Cancer Institute, 2004
• Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer
  Annals of Oncology, 2001
• Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
  Journal of Clinical Oncology, 2001
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
  Journal of Clinical Oncology, 1998